Andrew CFA - Arch Biopartners Acting Director

ARCH Stock

CAD 1.96 0.04 2.08%

Insider

Andrew CFA is Acting Director of Arch Biopartners

Age	58
Address	27 Street Clair Avenue East, Toronto, ON, Canada, M4T 2M5
Phone	647 428 7031
Web	https://www.archbiopartners.com

Arch Biopartners Management Efficiency

The company has return on total asset (ROA) of (0.812) % which means that it has lost $0.812 on every $100 spent on assets. This is way below average. Arch Biopartners' management efficiency ratios could be used to measure how well Arch Biopartners manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to climb to 14.13 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (2.8 K). At this time, Arch Biopartners' Total Current Assets are fairly stable compared to the past year. Intangibles To Total Assets is likely to climb to 0.32 in 2024, whereas Other Current Assets are likely to drop slightly above 39.8 K in 2024.

Compare Arch Biopartners to Peers

Predict price of Arch Biopartners

Arch Biopartners has accumulated 5.02 M in total debt. Arch Biopartners has a current ratio of 0.31, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Arch Biopartners until it has trouble settling it off, either with new capital or with free cash flow. So, Arch Biopartners' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Arch Biopartners sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Arch to invest in growth at high rates of return. When we think about Arch Biopartners' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Fahar Merchant	Medicenna Therapeutics Corp	67
	Adam MD	NervGen Pharma Corp	N/A
	Harold DMD	NervGen Pharma Corp	N/A
	Merle Boon	Perimeter Medical Imaging	N/A
	Samuel MD	Medicenna Therapeutics Corp	N/A
	Julien Muller	Nanalysis Scientific Corp	N/A
	Jeremy Sobotta	Perimeter Medical Imaging	N/A
	MBBS MD	Medicenna Therapeutics Corp	N/A
	Matt Zamora	Nanalysis Scientific Corp	N/A
	Susanne Riegel	Nanalysis Scientific Corp	N/A
	Brian McAlister	NervGen Pharma Corp	N/A
	Vladimir Pekar	Perimeter Medical Imaging	N/A
	Steve Sapot	Perimeter Medical Imaging	N/A
	Sean MSc	Nanalysis Scientific Corp	54
	Christopher Scott	Perimeter Medical Imaging	54
	Greg McFeetors	Nanalysis Scientific Corp	N/A
	Heather Phillips	Nanalysis Scientific Corp	N/A
	Rochelle Keen	Perimeter Medical Imaging	N/A

Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients. In addition, the company develops Borg, a Peptide-solid surface interface to inhibit biofilm formation and reduce corrosion and MetaMx synthetic molecules that targets brain tumor initiating cells and invasive glioma cells. ARCH BIOPARTNERS is traded on TSX Venture Exchange in Canada. Arch Biopartners (ARCH) is traded on TSX Venture Exchange in Canada and employs 7 people. Arch Biopartners is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Return On Asset

-0.81

Arch Biopartners Leadership Team

Elected by the shareholders, the Arch Biopartners' board of directors comprises two types of representatives: Arch Biopartners inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arch. The board's role is to monitor Arch Biopartners' management team and ensure that shareholders' interests are well served. Arch Biopartners' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arch Biopartners' outside directors are responsible for providing unbiased perspectives on the board's policies.

	Daniel MD, Chief CoFounder
	Andrew CFA, Acting Director
	Daniel Muruve, Chief Science Officer
	Paul Beck, CoFounder Scientist
	Aaron Benson, Director Communications
	Richard Muruve, President CEO, Director
	Justin MacDonald, CoFounder Scientist

Arch Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arch Biopartners a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Asset	-0.81
	Profit Margin	(1.86) %
	Operating Margin	(1.39) %
	Current Valuation	129.64 M
	Shares Outstanding	64.94 M
	Shares Owned By Insiders	19.86 %
	Number Of Shares Shorted	3.97 K
	Price To Sales	91.99 X
	Revenue	1.98 M
	Gross Profit	(502.88 K)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Arch Stock Analysis

When running Arch Biopartners' price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC